Home > Insider Trading > Filing (0001437749-15-005080)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1386858	Hyperion Therapeutics Inc	HPTX	Pharmaceutical Preparations (2834)	611512713

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1554403	A Christine Nash	C/O Hyperion Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA 94005	Svp & Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-03-10	10,000	$4.08	29,003	No	4	M	Direct
Common Stock	Disposition	2015-03-10	10,000	$35.08	19,003	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-03-12	10,000	$0.00	32,709	$4.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,709		2021-04-14	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 15, 2014.
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions ranging in price from $35.00-35.36. The reporting person undertakes to provide Hyperion Therapeutics, any security holder of Hyperion Therapeutics or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4.
The shares acquired upon exercise of portion of option exercised were fully vested and exercisable. The option began vesting on April 15, 2011, at a rate of 1/48th per month.